Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron Pharmaceuticals

Roche Holding AG

The World Health Organization began recommending the use of medicines called interleukin-6 receptor blockers as COVID-19 treatments for the severely ill, based on the findings of a large clinical study published Tuesday in JAMA. Roche Holding AG's Actemra and Sanofi and Regeneron Pharmaceuticals Inc.'s Kevzara are both approved in the U.S. as treatments for rheumatoid arthritis.

WHO recommends Roche, Sanofi/Regeneron drugs as COVID-19 treatments, calls for lower prices

French pharmaceutical giant Sanofi SA (LON:0O59) said Monday its Covid-19 vaccine developed in partnership with UK Pharma GlaxoSmithKline Plc (NYSE:GSK) could be ready for roll-out by December. Sanofi is one of the few global vaccine developers yet to roll out a Covid-19 vaccine, but things could change before the year ends.

As Sanofi launches its Covid vaccine by December, should you invest now?

AbbVie

British American Tobacco

Cardinal Health

Chevron

Imperial Brands PLC

Novartis

Realty Income Corp

Red Electrica Corp SA

Swiss Re AG

AT&T

Unilever

Exxon Mobil

Kiplinger "insights for investors" online, first listed 91 "Top Dividend Stocks From Around The World" 7/13/20. Two recent Kiplinger articles provided 102 Top Dividend Stocks on Earth as of 7/1/21. 39 European “Dividend Aristocrats,” show 10 years of stable or increasing dividends; 65 S&P 500 Aristocrats show 25 years of increases for U.S. companies.

102 'Top Dividend Stocks On Earth' July Update

Walmart

Eli Lilly

Novo Nordisk

The discount chain's private label sells at prices more than 50% lower than brand names made by Lilly, Sanofi, and Novo Nordisk.

Now on Sale at Walmart: Insulin That's Cheaper Than Brands from Lilly, Sanofi, or Novo Nordisk

Sanofi SA (NASDAQ: SNY) is working towards its R&D approach around mRNA to accelerate the development and delivery of next-generation vaccines. The company will invest approximately €400 million per year to build out its “end-to-end” internal capabilities in mRNA, the cell therapy technology.

Sanofi Invests To Build Internal Capabilities in mRNA

The vaccine heavyweight will invest nearly $480 million a year to develop mRNA vaccines for other diseases.

Sanofi Is Injecting Almost Half A Billion Dollars Each Year Into mRNA Tech Driving Pfizer, Moderna Covid Shots

Sanofi launches dedicated v accines mRNA Center of Excellence

Sanofi launches dedicated vaccines mRNA Center of Excellence

Amid a reorganization scheme aimed at slashing costs and prioritizing blockbuster immunology Dupixent, Sanofi SA (NASDAQ: SNY) will offload 16 consumer health products to Germany's Stada Arzneimittel.  Under the deal, which is expected to close in the third quarter, Stada will get its hands on the registrations, trademarks, and commercial rights for the products across 13 countries.

Sanofi Divests 16 Consumer Health Brands To Stada

Sanofi SA (NASDAQ: SNY) has announced new study data of Soliqua 100/33 (insulin glargine and lixisenatide injection) that met its two primary endpoints and all key secondary endpoints in a head-to-head comparison against premixed insulin in type 2 diabetes. The data were presented at the American Diabetes Association's 81st Scientific Sessions.

Sanofi's Soliqua Shows Improved Blood Sugar Control Without Weigh Gain Against Premixed Insulin

Regeneron (REGN) and partner Sanofi win EC approval for Libtayo for skin cancer and lung cancer.

Regeneron (REGN)/Sanofi's Libtayo Approved for Additional Indications

The European Commission (EC) has approved Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Libtayo (cemiplimab) for two additional indications - basal cell carcinoma (BCC) and non-small cell lung cancer with over 50% PD-L1 expression. BCC (skin cancer) approval covers adults with locally advanced or metastatic disease who have progressed on or are intolerant to a hedgehog pathway inhibitor.

Sanofi - Regeneron's Immunotherapy Scores European Approval For Skin And Lung Cancer Settings

Availability of the Q2 2021 Memorandum for modelling purposes

Sanofi: Availability of the Q2 2021 Memorandum for modelling purposes

Telesis Bio Inc

Sanofi (SNY) and Translate Bio begin a phase I study on an mRNA-based vaccine candidate against seasonal influenza.

Sanofi (SNY)/Translate Bio Begin Study on mRNA Flu Vaccine

Sanofi SA (SNY) at Guggenheim Biopharma Strategy Series Biopharma's Next Decade: Views from the Top on Global Strategy and Innovation Conference (Transcript)

Sanofi Pasteur, vaccine unit of Sanofi SA (NASDAQ: SNY) and Translate Bio Inc (NASDAQ: TBIO) have initiated a Phase 1 trial evaluating an mRNA-based investigational vaccine against seasonal influenza. The 280-subject trial will assess the safety and immunogenicity (immune response) of the monovalent (single-strain) mRNA-based flu vaccine candidate.

Sanofi, Translate Bio Initiate Early-Stage mRNA Influenza Vaccine Trial

-- Trial will evaluate potential of next generation of influenza vaccines with combined mRNA technology and flu vaccine development expertise -- -- Positive preclinical safety and immunogenicity data for mRNA influenza vaccine candidates support initiation of Phase 1 clinical trial --

Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influenza Vaccine

The European Commission approves Sanofi's (SNY) Aubagio for the treatment of pediatric patients aged 10 to 17 years with relapsing-remitting multiple sclerosis.

Sanofi's (SNY) Aubagio Gets EU Nod for MS in Pediatric Patients

The European Commission has approved Sanofi SA's (NASDAQ: SNY) Aubagio (teriflunomide) for the treatment of pediatric patients 10 to 17 years of age with relapsing-remitting multiple sclerosis (RRMS). The EC approval is based on data from the Phase 3 TERIKIDS study.

Europe Approves Sanofi's Expanded Use Of Aubagio In Pediatric Patients With Multiple Sclerosis

The FDA has approved Sanofi SA's (NASDAQ: SNY) newly completed plant in Swiftwater, Pennsylvania. The license will allow Sanofi to begin production of its Fluzone High-Dose vaccine for the 2021-22 flu season.

Sanofi Scores FDA Approval For Flu-Shot Facility In US

Sanofi SA's (NASDAQ: SNY) sutimlimab nailed all three of its primary endpoints in its Phase 3 CADENZA study for patients with cold agglutinin disease. This rare disorder can cause severe anemia without a recent history of blood transfusion.

Sanofi's Sutimlimab Hits Endpoint Goal In Rare Anemia Study After FDA Rejection

Sanofi SA (SNY) Presents at Goldman Sachs 42nd Annual Global Healthcare Conference (Transcript)

Amgen

AstraZeneca

BeiGene

Legend Biotech

A recent regulatory overhaul designed to speed up development and approval of new drugs in China has been welcomed by global pharma giants and local startups alike, aimed at bringing their latest cutting-edge treatments more quickly to Chinese patients.

Drug Startups Eye Quicker Profits Under China's New Fast-Track Approvals

Sanofi launches its new global employee share ownership plan

Sanofi (SNY) Management Presents on 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Conference (Transcript)

Sanofi SA (NASDAQ: SNY) has secured partners for a Phase 3 trial to study amcenestrant versus the hormone therapy tamoxifen in breast cancer. The Breast International Group (BIG), the European Organization for Research and Treatment of Cancer (EORTC), and the Alliance Foundation Trials (AFT) will initiate the pivotal trial.

News for Sanofi Stock (SNY)